Polimorfismos dos alelos m1 e m2 do gene CYP1A1: Susceptibilidade genética para o cancro do pulmão  by Mota, Paula et al.
R e v i s t a  P o r t u g u e s a  d e  P n e u m o l o g i a 89
Vol XVI  N.º 1  Janeiro/Fevereiro  2010
Artigo Original
Original Article
Resumo
O cancro do pulmão é considerado uma doença rela-
cionada com o meio ambiente, consequência da ex-
posição a agentes mutagénicos, nomeadamente os 
presentes no fumo do tabaco. O gene CYP1A1 codi-
fica a enzima aril hidrocarboneto hidroxilase (AHH), 
da fase I, do sistema multienzimático do citocromo 
P450, que desempenha uma função preponderante 
na bioactivação dos procarcinogénios do tabaco. Dois 
polimorfismos do CYP1A1, m1 (transição T6235C) 
e m2 (transição A4889G), estão associados a uma 
maior actividade enzimática, tendo sido referidos 
como factores genéticos de susceptibilidade para o 
cancro do pulmão.
Abstract
Lung cancer is considered an environment-related 
disease that develops as a consequence of exposure to 
mutagenic agents, namely those present in tobacco. 
The CYP1A1 gene codifies the phase I enzyme aryl 
hydrocarbon hydroxilase (AHH) belonging to the 
cytochrome P450 system that plays a major role in 
the bio-activation of tobacco procarcinogenes. Two 
CYP1A1 polymorphisms, m1 (T6235C transition) 
and m2 (A4889G transition), are associated with 
greater enzymatic activity and have been described as 
genetic susceptibility factors for lung cancer.
The aim of this study was to verify if this association 
holds true in blood samples of 175 lung cancer pa-
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Este trabalho teve como objectivo verificar esta pos-
sível associação em 175 doentes com cancro do pul-
mão e 217 controlos da Região Centro de Portugal, 
por RFLP (polimorfismo de comprimento de frag-
mentos de restrição).
Foi encontrada a seguinte distribuição para as frequên-
cias alélicas: 0.12 e 1.14, para os alelos mutados C e 
G, respectivamente, na população controlo. Os resul-
tados não revelaram significado estatístico quando 
comparados com a distribuição encontrada na popu-
lação de doentes. Relativamente à distribuição 
genotípica, a situação foi semelhante, não se registan-
do significado estatístico, mesmo quando foram con-
siderados genótipos de alto risco. Tal como noutras 
populações de diferente origem étnica, parece existir 
desequilíbrio de ligação para ambos os polimorfimos 
na população-controlo. Concluímos que nesta 
amostra de população portuguesa os polimorfismos 
m1 e m2 de CYP1A1 são particularmente raros, pare-
cendo não existir relevância clínica nem associação à 
susceptibilidade ao cancro do pulmão.
Rev Port Pneumol 2010; XVI (1): 89-98
Palavras-chave: Cancro do pulmão, tabaco, citocro-
mo p450, CYP1A1, desequilíbrio de ligação.
tients and 217 non-cancer patients from Portugal’s 
midlands region. The samples were studied by restric-
tion fragment length polymorphism (RFLP) assay.
The allelic frequencies of the mutant alleles were 0.12 
for allele C and 1.14 for allele G in the control popu-
lation. The results were not statistically different from 
those alleles in the patient population. There was also 
no statistically significant difference in genotype dis-
tribution in lung cancer patients and controls even 
when combining high risk genotypes. In our control 
sample, as in other populations of different ethnic 
origin, both polymorphisms also seem to be in lin-
kage disequilibrium. We conclude that in this sample 
of the Portuguese population, CYP1A1 m1 and m2 
polymorphisms are too rare to be of clinical relevance, 
and do not seem to be associated with susceptibility 
to lung cancer.
Rev Port Pneumol 2010; XVI (1): 89-98
Key-words: Lung cancer, smoking, cytochrome 
P450, CYP1A1, linkage disequilibrium.
Introduction
Cancer arises as a result of a complex se-
quence of mutational events that contributes 
to the breakdown of regulatory mechanisms, 
such as cell cycle control, apoptosis and dif-
ferentiation. Some of the genes involved in 
these mechanisms, such as TP53, KRAS, or 
RB1, may become mutated after environ-
mental carcinogenic exposure. Inter-indi-
vidual variations in the activity of detoxify-
ing enzymes such as cytochrome P450 
enzymes, glutathione S-transferase (GSTs) 
and N-acetyltransferases (NATs) are also im-
portant in susceptibility to cancer1-4. Genetic 
polymorphisms explain these functional dif-
ferences. The search for susceptible genetic 
profiles is a new and promising field of pre-
ventive medicine. Two main approaches 
have been used: the search for specific candi-
date genes and genome-wide searches based 
on microarray technologies. We followed 
the former, classical approach to search for 
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genetic polymorphisms associated with sus-
ceptibility to sporadic lung cancer.
Lung cancer is the leading worldwide cause 
of mortality5,6. In Portugal it is the third 
highest cause of death and the leading cause 
of cancer death. In lung cancer, both expo-
sure to chemical agents, such as polycyclic 
aromatic hydrocarbons (PAH) in cigarette 
smoke and nitrosamines and inherited dif-
ferences in metabolic capacity are thought 
to play a primary role in carcinogenesis7,8. 
Smoking appears to be responsible for 85% 
of lung cancer in the Portuguese popula-
tion9. In addition to tobacco compounds, 
other carcinogens such as alcohol, radon, 
silica and diesel exhaust particles may also 
contribute10,11.
The cytochrome P450 is a multi-enzymatic 
system involved in Phase I metabolism of a 
wide range of structurally diverse subs-
trates12. P450 enzymes insert molecular 
oxygen, increasing the hydrophility and ex-
cretion of substrates from the cell13. The en-
zyme aryl hydrocarbon hydroxilase (AHH), 
codified by the CYP1A1 gene, belongs to 
the cytochrome P450 system and is respon-
sible for the activation of PAH such as 
benzo(a)pyrene and coronene14. More spe-
cifically, AHH catalyses the transformation 
of PAH to the BP-7.8-epoxide form which 
is further oxidised to BP-7.8-dihydrodiol by 
the epoxide hydrolyse (EH) enzyme. BP-
7.8-dihydrodiol is then transformed by 
AHH to BP-7.8-dihydrodiol-9.10-epo-
xide15,16. PAH metabolites are powerful car-
cinogens responsible for countless muta-
tions present in squamous cell carcinomas 
(SCC) of the lung. PAH also work as power-
ful inducers of CYP1A1 gene product by 
binding to a citosolic receptor, the transcrip-
tion factor aryl hydrocarbon receptor that 
ultimately activates and regulates the ex-
pression of the gene13,17-19.
It has been demonstrated that AHH expres-
sion is induced in the bronchial airways of 
more than 80% of lung cancer patients who 
are smokers20, presumably due to the high 
concentration of PAH and other carcino-
gens present in tobacco smoke. As a result, 
the relative levels of CYP1A1 expression in 
bronchi have been linked to the pathoge-
nesis of tobacco induced lung cancer.
CYP1A1 gene is located in chromosome 
15q22–q24 and in addition to the lung it is 
also expressed in the liver, gastrointestinal 
tract, brain, lymphocytes and macropha-
ges21,22. Four different polymorphisms of 
CYP1A1 gene, m1, m2, m3 and m4 have 
been described23 and the m4 polymorphism 
has a very low frequency in Caucasian po-
pulations. The m1 and m2 polymorphisms 
are more widely studied not only due to 
their higher genotype frequency but also 
their possible involvement in lung carcino-
genesis24. The m1 polymorphism, involving 
an MspI restriction site, is a T6235C transi-
tion in the 3’ non-coding region of the gene, 
250 bp downstream from the polyadenyla-
tion site20. The nucleotide substitution ap-
pears to be associated with increasing levels 
of CYP1A1 expression in response to PAH25. 
The m2 polymorphism is an A4889G tran-
sition in exon 7 leading to an isoleucine to a 
valine exchange and involves a BsrDI restric-
tion site26. The amino acid exchange lies 
within the hem-binding region of the pro-
tein and has been shown to increase the 
catalytic activity of the enzyme seven-fold27. 
As AHH activates procarcino genes, indi-
viduals with high CYP1A1 gene inducibility 
or increased enzymatic activity may be more 
susceptible to the carcinogens of tobacco 
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smoke and to developing lung cancer. Re-
cent studies have suggested that m2 and m1 
polymorphisms are probably involved in 
linkage disequilibrium25,28, but this remains 
a controversial issue.
The present study aimed to evaluate the im-
portance of CYP1A1 polymorphisms as 
susceptibility factors for lung cancer and to 
verify the existence of the allelic linkage di-
sequilibrium.
Materials and methods
Cases and controls
The lung cancer cases consisted of 175 pa-
tients (130 males and 45 females; average age 
± SD = 62.1 ± 10.2 yrs) who were followed 
in the Pulmonology Department of the Hos-
pital da Universidade de Coimbra, Portugal. 
Histological diagnosis was performed accord-
ing to the WHO 2004 classification. The 
control group included 217 unrelated volun-
teers (143 males and 74 females; mean age ± 
SD = 70.8 ± 11.8 yrs) who had no history of 
cancer and as age and gender have never been 
shown to influence CYP 450 polymor-
phisms29. All individuals were from Portugal’s 
midlands region and Caucasian. Informed 
consent from patients, as well as from con-
trols was obtained together with permission 
from the Ethics Committee.
Methods
DNA was extracted from frozen peripheral 
blood using the urea DNA extraction tech-
nique. DNA concentration was verified us-
ing a spectrophotometer (UV-160A-Shi-
madzu). CYP1A1 m1 and m2 genotypes 
were characterised using RFLP assay.
For m1 polymorphism, a PCR was carried 
out in a total volume of 50μl containing 200 
ng of DNA, 1x reaction buffer, 1.5 mM of 
MgCl2 , 200 μM of dNTPs, 5 % of dimethyl 
sulfoxide, 0.2 μM of primer forward (5’ TAG 
GAG TCT TGT CTC ATG CCT 3’), 0.2 
μM of primer reverse (5’ CAG TGA AGA 
GGT GTA GCC GCT 3’), and 1U Taq 
DNA Polymerase (Bioline). The samples 
were amplified using a thermal cycler with an 
initial denaturation at 94ºC for 5 mins fol-
lowed by 30 cycles with denaturation at 94ºC 
for 30 seconds, annealing at 62ºC for 60 se-
conds and primer extension at 72ºC for 60 
seconds, followed by a final extension step at 
72ºC for 5 mins. The PCR products were 
then analysed in a 1% agarose gel with ethid-
ium bromide and visualised using a UV tran-
silluminator. For RFLP assay, digestion was 
carried out overnight at 37ºC, in a total vol-
ume of 15 μl containing 5 μl of PCR prod-
uct, 1x buffer and 3U Msp I In the pre sence 
of the 6235C polymorphism, the enzyme 
MspI, digested the 340 bp PCR pro duct in 
two bands of 200 and 140 bp. The wild type 
6235C form corresponds to the absence of 
the restriction site.
For CYP1A1 m2, the PCR was carried out 
in a total volume 50 μl containing 200 ng of 
DNA, 1x reaction buffer, 1.5mM of MgCl2, 
200 μM of dNTPs, 5% of dimethyl sulfo-
xide, 0.2 μM of primer forward 5’ CAG 
ACC AGG TAG ACA GAG 3’, 0,2 μM of 
primer reverse 5’ GTC CAC CCT CTT 
AAG CTC T 3’ and 1U Taq DNA Poly-
merase (Bioline). The PCR protocol was 
carried out in the same thermal cycler with 
an initial denaturation at 94ºC for 5 mins 
followed by 30 cycles of denaturation at 
94ºC for 30 seconds, annealing at 61ºC for 
60 seconds and primer extension at 72ºC 
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for 60 seconds. The PCR products were 
analysed in a 1% agarose gel with ethidium 
bromide and visualised using a UV transil-
luminator. For RFLP assay, digestion was 
carried out overnight at 65ºC in a total vo-
lume of 15 μl containing 5 μl of PCR pro-
duct, 1x buffer and 4U of BsrDI. In the 
presence of the 4889G polymorphism, the 
enzyme BsrDI, digested the 350 bp PCR 
product in two bands of 232 and 128 bp. 
The 4889A wild type polymorphism corres-
ponds to the absence of the restriction site.
Statistical analysis
The odds ratio (OR) with the correspond-
ing 95% confidence interval (CI) and Pear-
son chi-square test of independence (χ2) 
were used in data analysis. The level of sig-
nificance was set at p<0.05.
Results
The histological diagnosis included squamous 
cell carcinoma, adenocarcinoma and small 
cell carcinoma. Table I shows the frequency 
of the histological types studied. Table II de-
picts the allelic frequencies in the tumoral 
and control populations. There were no sta-
tistically significant differences in the allelic 
frequencies in the tumoral and control group. 
The distribution of genotype frequencies for 
both polymorphisms is shown in Table III. 
As it is rare to find patients homozygous for 
the variant alleles C and G, homozygous and 
heterozygous were analysed together. In the 
patient group there were only 3 individuals 
homozygous for C allele and 2 homozygous 
for G allele and in the control group there 
were only 4 homozygous for C allele and 1 
for G allele. There were also no statistically 
significant differences between the two 
groups. That were shown to be in the Hardy-
Weinberg equilibrium (p>0.05). We also 
analysed the frequency of individuals simul-
taneously homozygous for both polymor-
phisms associated with lower enzymatic ac-
tivity (TT and GG), expecting they would 
be represented higher in the control group, 
but no significant difference was found be-
tween patients and controls. Fig. 1 illustrates 
the analysis of genotypes using RFLP assays.
Table I – Distribution of histological diagnosis in patients
Histological type No. of patients
Adenocarcinoma 59 (34%)
Squamous cell carcinoma 53 (30%)
Small-cell carcinoma 33 (19%)
Others* 30 (17%)
* Others = pleomorphic carcinoma, neuroendocrine carcinoma ade-
 nosquamous carcinoma, non-small-cell carcinoma and giant cell 
carcinoma
Table II – Distribution of allelic frequencies in the two groups
Alleles Patients Controls OR95% CI p (χ
2)
m1
T 0.90 0.88
1.3 (0.7-2.4) 0.964(0.002)
C 0.10 0.12
m2
A 0.89 0.86
1.3 (0.7-2.4) 0.950(0.004)
G 0.11 0.14
Table III – Distribution of genotype frequencies
Patients
No. (%)
Controls
No. (%) OR (95% CI)
χ2 p
m1
T/T 142 (81.2%) 161 (74.2%) 1.5 (0.9-2.4) 0.103T/C 
C/C
and 33 (18.8%) 56 (25.8%)
m2
A/A 137 (78.3%) 168 (77.4%) 1.1 (0.7-1.7) 0.838G/A 
G/G
and 38 (21.7%) 49 (22.6%)
Total 175 217
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Among the different histological types of lung 
cancer, as squamous cell carcinoma is sup-
posed to be more frequently associated with 
environmental toxic exposure, we analysed 
any difference between the distribution of the 
genotypes in the different types of carcinomas 
(Table IV). No statistically significant diffe-
rence was found. Nevertheless, we found a 
small statistical significance (p=0.049) when 
we compared the allelic distribution for m2 
allele in adenocarcinoma and small-cell carci-
noma, and when we considered the small and 
squamous cell association and the other histo-
logical types (p=0.058). Although our sam-
ples included very few homozygous geno-
types, we analysed if there was any suggestion 
 ϕX 1 2 3 4 5 6
Fig. 1 – Different fragments from Msp I and Bsr DI digestions. ϕX molecular weight; 1- 
m1:TT, homozygous wild type (340bp); 2- m1: homozygous CC (200bp and 140bp frag-
ments); 3- m1: heterozygous TC (340bp, 200bp and140bp fragments); 4- m2: AA, ho-
mozygous wild type (350bp fragment); 5-m2: heterozygous AG, (350bp, 232bp and 
118bp fragments); 6 –m2: GG, homozygous double mutated (232bp,118bp fragments)
Table IV – Distribution of genotypes in different histological types of lung cancer
 Genotypes
Histological types
m1
p (χ2)
m2
p (χ2)
TT TC/CC AA AG/GG
Adenocarcinoma 42 (0.74) 15 (0.26)
0.380
42 (0.74) 15 (0.26)
0.180Small-cell carcinoma 28 (0.85) 5 (0.15) 30 (0.91) 3 (0.09)Squamous cell carcinoma 39 (0.85) 7 (0.15) 37 (0.80) 9 (0.20)
Others* 33 (0.85) 6 (0.15) 28 (0.72) 11 (0.28)
* Others = pleiomorphic carcinoma, neuroendocrine carcinoma, adenosquamous carcinoma, non-small-cell carcinoma, giant cell carcinoma
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of allele linkage disequilibrium in the control 
population for the higher risk genotypes. The 
results shown in Table V, where the number 
of observed and expected individuals is com-
pared for each combined genotype, support 
the existence of linkage disequilibrium.
Discussion
The aim of this work was to define a corre-
lation between the two most widely studied 
CYP1A1 gene polymorphisms, m1 allele 
(T6235C transition) and m2 allele (A4889G 
transition) and susceptibility to lung cancer. 
The allele and genotype frequencies found 
in our population samples were quite simi-
lar to those described in other Caucasian 
populations30-33. The low frequency of the 
high-risk genotypes in Caucasian popula-
tions complicates data analysis. Only in 
populations of Asian origin do the frequen-
cies of C and G alleles and of correspondent 
homozygous genotypes have higher fre-
quencies. For example, frequency for the 
m1 heterozygous is 0.171 in our lung can-
cer population is half of the frequency found 
in the Chinese population (0.395). We also 
describe a frequency of 0.017 for m1 ho-
mozygous, while in the Mongol population 
the frequency is 0.22817.
The results described in Table III analyse 
the association between the two polymor-
phisms m1 and m2 and the risk of lung can-
cer. Though no statistically significant dif-
ference could be found (p>0.05), the 
unexpected fact is that the homozygous 
genotype for the wild genotypes was more 
frequent in patients, especially for m1 poly-
morphism (OR=1.5; 95% CI 0.9-2.4). It is 
likely that results would be different with 
more extended samples including more ho-
mozygous for the mutant high-risk geno-
types. We also found no association between 
the major histological types (Table IV). 
Nevertheless when we analysed the allelic 
distribution of m2 polymorphism, we found 
a small statistical significance in terms of 
adenocarcinoma and small-cell carcinoma 
(p=0.049) and also between small and 
squamous cells and the other histological 
types (p=0.058).
In Asian populations, where the mutant al-
leles reach higher frequencies, CYP1A1 m1 
and m2 polymorphisms have been widely 
described as genetic susceptibility factors for 
environmentally associated lung cancer for 
both squamous cell and adenocarcino-
ma20,34,35. An association between the pre-
sence of at least one copy of the mutant m1 
allele and increased risk for squamous cell 
carcinoma (OR=2.4; 95% CI of 1.2-4.7) 
was found in more mixed populations, in-
cluding Japanese, Hawaiian and Caucasians 
by Le Marchand et al.36. No statistically sig-
nificant difference was found for the mu-
tant m2 allele in terms of lung cancer in 
general and for other histological types. In 
Caucasian populations, results remain con-
troversial and many other authors also could 
not find any association30,32,33. Other inves-
tigators studied both CYP1A1 polymor-
Table V – Linkage disequilibrium analysis in the control 
population
Genotypes m 2 - AA m2 - AG m2 - GG p(x2)
m1 - TT
m1 – TC
m1 - CC
134 (84*)
31 (39*)
3 (5*)1
27 (35*)
21 (35*)
0 (6*)1
0 (4*)1
0 (6*)1
1 (3*)1
0.001 
(15.968)
* Expected number of individuals for the genotype
1 Considering the null value the correlation wasn’t tested
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phism and Phase II enzyme polymorphisms, 
known to influence excretion of genotoxic 
compounds. Montserrat Garcia-Closas et 
al.31 found that while neither the CYP1A1 
MspI heterozygous genotype alone nor the 
GSTM1 null genotype alone were associa-
ted with a significant increase in lung cancer 
risk, both genetic traits are associated with a 
twofold increase in risk (95% CI 1.0-3.4).
The inconsistency of results remains when 
the association between genotypes, the dose 
level of tobacco exposure and susceptibility 
to lung cancer is studied. For instance, Na-
kachi et al.37 showed that individuals with the 
m1 susceptible genotype were at a remar-
kably higher risk at a low dose level of ciga-
rette smoke (OR=7.31; 95% CI 2.13-25.12) 
and that the difference in susceptibility be-
tween genotypes was reduced at high dose 
levels. On the contrary, Montserrat Garcia-
Closas et al.31 could not find enough evidence 
for a substantial modification of the effect of 
tobacco pack-years on lung cancer risk by the 
CYP1A1 m1 and GSTM1 genotypes. In a 
pooled analysis, Le Marchand et al.27 found a 
trend to an overrepresentation of m1 poly-
morphism in lung cancer patients, especially 
in non-smokers and in women.
In multifactorial cancer, the risk conferred 
by these polymorphisms, generally called 
SNPs (from single nucleotide polymor-
phisms), is typically small to moderate, with 
small odds ratios generally with wide confi-
dence intervals. Results are also often con-
flicting. One cause for these discrepancies is 
the sample size. As these are low penetrance 
polymorphisms, each one having little in-
fluence on the overall risk, large population 
studies are needed. But even within popula-
tions of thousands of individuals, results of-
ten remain inconclusive. Recently, microar-
ray technology has allowed a simultaneous 
study of multiple polymorphisms and hope-
fully it will allow the discovery of genetic 
profiles for disease predisposition38, even 
though these technologies are very expen-
sive, demand huge population samples and 
are very prone to statistical errors.
The possibility of allelic linkage disequili-
brium for m1 and m2 genotypes has been 
suggested but never confirmed. In our con-
trol sample we also found a suggestion of 
the linkage (p< 0.001), explaining the simi-
larity of results for the two alleles. Linkage 
disequilibrium has been proved to be asso-
ciated with evolutionary mechanisms that 
select functionally important loci39.
In the future some other important issues 
must be studied. An important point is the 
relation between smoking and CYP1A1 
polymorphisms. The time of exposure, the 
number of cigarettes and the age at starting 
smoking are important to confirm the rela-
tion between the polymorphisms and the 
increasing susceptibility to developing lung 
cancer. These issues are still under debate 
and controversial results have been pub-
lished. The relationship between Phase I en-
zymes such as CYP1A1 and Phase II en-
zymes such as GSTM1 is another important 
parameter for understanding the influence 
of the activation and detoxification of car-
cinogens and the development of lung can-
cer. The study of other regulator genes such 
as GSTM1, CYP2D6 and NAT2 and their 
association with the presence of mutations 
in the tumour suppressor gene TP53 is al-
ready in course and will allow a better un-
derstanding of lung cancer carcinogenesis. 
Future studies should also include environ-
mental exposure to other toxins, as well as 
diet factors such as alcohol.
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In conclusion, we did not find any statisti-
cally significant difference in allelic and 
geno type frequency in the populations stu-
died. Apparently there is no association be-
tween CYP1A1 m1 and m2 polymorphisms 
and susceptibility to lung cancer. Neverthe-
less, the p values found between squamous 
and small-cell and the other histological 
types and also for adenocarcinoma and 
small-cell confirm the controversial results 
involving these studies and suggest that the 
population should be extended to obtain 
unequivocal results. As the statistical analysis 
suggests the existence of allele linkage di-
sequilibrium in the Portuguese population, 
the simultaneous study of the two alleles in 
future investigations seem unnecessary.
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